Company intelligence / Profile preview

Aryx Pharmaceuticals

Fremont, California, United States

Ownership: Private
Development stage: Other

Overview

ARYx developed multiple drug candidates using retrometabolic design to create safer versions of existing drugs. Tecarfarin achieved Phase 2/3 for anticoagulation, budiodarone reached Phase 2 for atrial fibrillation, and ATI-7505 completed Phase 2b for chronic constipation showing statistical significance at 80mg twice daily dose with clinically meaningful increase in spontaneous bowel movements.

Therapeutic areas: GastroenterologyCardiovascularPsychiatry
Modalities: Small molecule
Industry: Biotech

Partnerships

Procter & Gamble (program: ATI-7505, status: Terminated in 2008)

Beyond the preview

Go deeper on Aryx Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aryx Pharmaceuticals.

Explore the full profile